Redmile Group, LLC's Net Worth

$47.8 Million

Estimate Recalculated Sep 18, 2024 08:22PM EST

Who is Redmile Group, LLC?

Redmile Group, LLC has an estimated net worth of $47.8 Million. This is based on reported shares across multiple companies, which include ALDER BIOPHARMACEUTICALS INC, XERIS PHARMACEUTICALS INC, RayzeBio, Inc., Allakos Inc., Science 37 Holdings, Inc., PLIANT THERAPEUTICS, INC., Stoke Therapeutics, Inc., Absci Corp, Adagio Therapeutics, Inc., Gritstone Oncology, Inc., Entrada Therapeutics, Inc., Repare Therapeutics Inc., Allovir, Inc., IGM Biosciences, Inc., Verve Therapeutics, Inc., Nurix Therapeutics, Inc., Akero Therapeutics, Inc., Replimune Group, Inc., AMICUS THERAPEUTICS INC, FATE THERAPEUTICS INC, Kymera Therapeutics, Inc., Beam Therapeutics Inc., Augmedix, Inc., Neoleukin Therapeutics, Inc., Syros Pharmaceuticals, Inc., Atreca, Inc., VAPOTHERM INC, Shattuck Labs, Inc., TCR2 THERAPEUTICS INC., HOOKIPA Pharma Inc., Cabaletta Bio, Inc., Annexon, Inc., MedAvail Holdings, Inc., Aprea Therapeutics, Inc., ARRAY BIOPHARMA INC, Zymeworks Inc., and ADC Therapeutics SA.

SEC CIK

Redmile Group, LLC's CIK is 0001425738

Past Insider Trading and Trends

2024 was Redmile Group, LLC's most active year for acquiring shares with 20 total transactions. Redmile Group, LLC's most active month to acquire stocks was the month of December. 2016 was Redmile Group, LLC's most active year for disposing of shares, totalling 5 transactions. Redmile Group, LLC's most active month to dispose stocks was the month of June. 2024 saw Redmile Group, LLC paying a total of $30,511,754.97 for 8,297,647 shares, this is the most they've acquired in one year. In 2023 Redmile Group, LLC cashed out on 5,000,000 shares for a total of $15,000,000.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

ALDER BIOPHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-8.24M
—
—
0
Oct 22
Form 4
—
0
—
—
0
Jun 30
Form 4
—
0
—
—
0
May 23
Form 4
+26.73%
1.74M
$11.50
$19,999,995.00
8.24M
Mar 4
Form 4
—
0
—
—
0
Dec 31
Form 4
—
0
—
—
0
Jun 30
Form 4
—
0
—
—
0
May 23
Form 4
—
0
—
—
0
Apr 25
Form 3
—
0
—
—
0
No matching records found

XERIS PHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+24.37%
588K
$10.00
$5,880,000.00
3M
Feb 19
Form 4
∞
2.41M
$15.00
—
2.41M
Jun 25
Form 3
—
0
—
—
0
No matching records found

RayzeBio, Inc. (RYZB) No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
∞
1.86M
—
—
1.86M
Sep 19
Form 3
—
0
—
—
0
No matching records found

Allakos Inc. (ALLK) Snapshot price: $0.648

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
∞
1.01M
—
—
1.01M
Jul 23
Form 3
—
0
—
—
0
No matching records found

Science 37 Holdings, Inc. (SNCE) No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-1.02M
$5.75
-$5,848,917.25
0
Mar 12
Form 4
+2.49%
494.85K
$0.25
$124,999.87
20.34M
May 11
Form 4
—
0
$3.38
—
39.7M
Jun 13
Form 4
+0.21%
40.98K
$3.05
$124,998.15
19.85M
May 23
Form 4/A
+296.16%
14.81M
—
—
19.81M
Oct 6
Form 4
—
0
—
—
0
Oct 7
Form 4
+295.02%
14.75M
—
—
19.75M
Oct 6
Form 3
—
0
—
—
0
No matching records found